Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting ...

Market access is about aligning internal strategies with external realities that often change without warning and at a ...

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating ...

The afternoon of day 2 at Asembia’s AXS25 Summit offered various intriguing sessions to pick from, including one on ...

Will Pih, co-founder, Two Labs, explains how specialty pharmacies and manufacturers are adapting to financial pressures in rare disease care through patient-centric services, hub innovation, and ...

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global ...

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase ...

The submission is backed by clinical data from over 2,100 patients, including two pivotal Phase III trials in patients ...

The emerging biotech scene in Chicago has the potential to develop new treatments and technologies, but funding cuts from the ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...